2024
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients
Cheng H, Shevach J, Castro E, Couch F, Domchek S, Eeles R, Giri V, Hall M, King M, Lin D, Loeb S, Morgan T, Offit K, Pritchard C, Schaeffer E, Szymaniak B, Vassy J, Katona B, Maxwell K. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients. JAMA Oncology 2024, 10: 1272-1281. PMID: 39052257, DOI: 10.1001/jamaoncol.2024.2185.Peer-Reviewed Original ResearchBRCA1/2 PVCancer riskPoly ADP-ribose polymeraseGenetic testingCancer genetic testingFamilial cancer riskPrimary care cliniciansEvidence of increased riskBRCA1/2-PV carriersMale carriersIncreased genetic testingRisk of breastRisk reductionCancer early detectionCancer-predisposing variantsClinical trial opportunitiesCancer therapy optionsCare cliniciansTargeted risk managementCancer screeningPV carriersHereditary cancerADP-ribose polymeraseGuideline recommendationsEarly cancer detection
2014
Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.
Carroll P, Parsons J, Andriole G, Bahnson R, Barocas D, Catalona W, Dahl D, Davis J, Epstein J, Etzioni R, Giri V, Hemstreet G, Kawachi M, Lange P, Loughlin K, Lowrance W, Maroni P, Mohler J, Morgan T, Nadler R, Poch M, Scales C, Shanefelt T, Vickers A, Wake R, Shead D, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. Journal Of The National Comprehensive Cancer Network 2014, 12: 1211-9; quiz 1219. PMID: 25190691, DOI: 10.6004/jnccn.2014.0120.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsProstate cancer early detectionCancer early detectionNCCN guidelinesProstate cancerEarly detectionNCCN Guidelines InsightsNotable recent updatesProstate Health IndexEarly Detection ProgramRecent FDA approvalMultiple risk variablesBiopsy decisionsFDA approvalDetection programRisk variablesCancerHealth indexRecent updatesMenGuidelinesBiopsy
2012
Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer among High-Risk Men Enrolled in Prostate Cancer Early Detection
Hughes L, Zhu F, Ross E, Gross L, Uzzo R, Chen D, Viterbo R, Rebbeck T, Giri V. Assessing the Clinical Role of Genetic Markers of Early-Onset Prostate Cancer among High-Risk Men Enrolled in Prostate Cancer Early Detection. Cancer Epidemiology Biomarkers & Prevention 2012, 21: 53-60. PMID: 22144497, PMCID: PMC3253936, DOI: 10.1158/1055-9965.epi-11-0727.Peer-Reviewed Original ResearchConceptsEarly-onset prostate cancerProstate cancer early detectionHigh-risk menCancer early detectionAfrican American menProstate cancerEarly detectionAmerican menConcordance indexClinical informationProstate cancer risk assessmentCancer diagnosisHarrell's concordance indexAfrican American raceFamilial prostate cancerUseful clinical informationCancer risk assessmentStudy criteriaLongitudinal cohortFamily historyAge 35Clinical roleCox modelEligibility criteriaAmerican race
2009
Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men
Giri V, Egleston B, Ruth K, Uzzo R, Chen D, Buyyounouski M, Raysor S, Hooker S, Torres J, Ramike T, Mastalski K, Kim T, Kittles R. Race, Genetic West African Ancestry, and Prostate Cancer Prediction by Prostate-Specific Antigen in Prospectively Screened High-Risk Men. Cancer Prevention Research 2009, 2: 244-250. PMID: 19240249, PMCID: PMC2652509, DOI: 10.1158/1940-6207.capr-08-0150.Peer-Reviewed Original ResearchConceptsBaseline prostate-specific antigenProstate-specific antigenSelf-reported raceAfrican American menProstate cancerAmerican menProstate Cancer Risk Assessment ProgramCancer Risk Assessment ProgramEarly detectionProstate cancer early detectionHigh-risk cohortWest African ancestryAfrican American raceHigh-risk menLow PSA valuesProportional hazards modelRace-specific differencesProstate cancer predictionCancer early detectionEuropean American menAfrican ancestryHazard ratioPSA valuesFamily historyBRCA1/2 mutations